Login to Your Account

Histogenics $49M Round to Advance NeoCart Implant

By Marie Powers
Staff Writer

Wednesday, August 8, 2012

Regenerative medicine developer Histogenics Corp. said Tuesday that it completed a $49 million financing to complete its ongoing Phase III program for lead candidate NeoCart, an autologous neocartilage tissue implant that utilizes a patient's own cells to regenerate articular cartilage in the knee. The trial is currently enrolling patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription